A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients with Advanced, Refractory or Recurrent Solid Tumors
NCT #
not yet registered
Condition(s)
Breast Cancer, Solid Tumor
Molecular Target(s)
CMTR2
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule (Targeted)
Agents(s)
AT-1965
Phase(s)
I/II
Mechanism of Action
AT-1965 is a CMTR2 inhibitor
Purpose
- This study is being done to find out if a new investigational drug, AT-1965, is safe when given to you.
- It aims to assess the pharmacokinetics (PK) to measure how your body takes up, breaks down, and clears AT-1965.
- Additionally, it will evaluate the Pharmacodynamics (PD) to show how your body responds to the drug.
- The study also aims to analyze the antitumor activity to measure how AT-1965 works in your tumors.
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.